Tranexamic acid in trauma: How should we use it?

Journal of Trauma and Acute Care Surgery

Volumn 74, Issue 6, 2013, Pages 1575-1586

  Napolitano, Lena M ^a   Cohen, Mitchell J ^b   Cotton, Bryan A ^c   Schreiber, Martin A ^d   Moore, Ernest E ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; AMINOCAPROIC ACID; APROTININ; PLACEBO; TRANEXAMIC ACID;

BLEEDING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; COST EFFECTIVENESS ANALYSIS; DEATH; ERYTHROCYTE TRANSFUSION; FIBRINOLYSIS; HEART INFARCTION; HEMORRHAGIC SHOCK; HUMAN; HYPERFIBRINOLYSIS; INJURY; MEDICINE; MEDLINE; MENORRHAGIA; MORTALITY; OPERATIVE BLOOD LOSS; POSTPARTUM HEMORRHAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESUSCITATION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; TRAUMATIC BRAIN INJURY; WORLD HEALTH ORGANIZATION;

ANTIFIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; THROMBELASTOGRAPHY; TRANEXAMIC ACID; TREATMENT OUTCOME; WOUNDS AND INJURIES;

EID: 84880095773     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e318292cc54     Document Type: Review

References (83)

1. Kashuk JL, Moore EE, Sawyer M, Wohlauer M, Pezold M, Barnett C, Biffl WL, Burlew CC, Johnson JL, Sauaia A. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. Ann Surg. 2010;252:434-442; discussion 443-444.
2. Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care. 2007;13: 680-685.
3. Ganter MT, Pittet JF. New insights into acute coagulopathy in trauma patients. Best Pract Res Clin Anaesthesiol. 2010;24:15-25.
4. Brohi K, Cohen MJ, Ganter MT, Matthay MA, Mackersie RC, Pittet JF. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? Ann Surg. 2007;245:812-818.
5. Brohi K, Cohen MJ, Ganter MT, Schultz MJ, Levi M, Mackersie RC, Pittet JF. Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. J Trauma. 2008;64:1211-1217; discussion 1217.
6. Carroll RC, Craft RM, Langdon RJ, Clanton CR, Snider CC, Wellons DD, Dakin PA, Lawson CM, Enderson BL, Kurek SJ. Early evaluation of acute traumatic coagulopathy by thrombelastography. Transl Res. 2009; 154:34-39.
7. Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, David JS. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth. 2008;100:792-797.
8. Schochl H, Frietsch T, Pavelka M, Jambor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009;67:125-131.
9. Tauber H, Innerhofer P, Breitkopf R, Westermann I, Beer R, El Attal R, Strasak A, Mittermayr M. Prevalence and impact of abnormal ROTEM(R) assays in severe blunt trauma: results of the 'Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study'. Br J Anaesth. 2011;107:378-387.
10. Cohen MJ. Towards hemostatic resuscitation: the changing understanding of acute traumatic biology, massive bleeding, and damagecontrol resuscitation. Surg Clin North Am. 2012;92:877-891, viii.
11. Martini WZ. Fibrinogen availability and coagulation function after hemorrhage and resuscitation in pigs. Mol Med. 2011;17:757-761.
12. Kutcher ME, Redick BJ, McCreery RC, Crane IM, Greenberg MD, Cachola LM, Nelson MF, Cohen MJ. Characterization of platelet dysfunction after trauma. J Trauma Acute Care Surg. 2012;73:13-19.
13. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma. 2003;54:1127-1130.
14. Cohen MJ, Call M, Nelson M, Calfee CS, Esmon CT, Brohi K, Pittet JF. Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients. Ann Surg. 2012;255: 379-385.
15. Hess JR, Brohi K, Dutton RP, Hauser CJ, Holcomb JB, Kluger Y, Mackway-Jones K, Parr MJ, Rizoli SB, Yukioka T, et al. The coagulopathy of trauma: a review of mechanisms. J Trauma. 2008;65:748-754.
16. Davenport R. Pathogenesis of acute traumatic coagulopathy. Transfusion. 2013;53(Suppl 1):23S-27S.
17. Kutcher ME, Cripps MW, McCreery RC, Crane IM, Greenberg MD, Cachola LM, Redick BJ, Nelson MF, Cohen MJ. Criteria for empiric treatment of hyperfibrinolysis after trauma. J Trauma Acute Care Surg. 2012;73:87-93.
18. Cohen MJ, Brohi K, Ganter MT, Manley GT, Mackersie RC, Pittet JF. Early coagulopathy after traumatic brain injury: the role of hypoperfusion and the protein C pathway. J Trauma. 2007;63:1254-1261; discussion 61-62.
19. Esmon CT. The protein C pathway. Chest. 2003;124(Suppl):26S-32S.
20. Davidson CJ, Tuddenham EG, McVey JH. 450 million years of hemostasis. J Thromb Haemost. 2003;1:1487-1494.
21. Genet GF, Ostrowski SR, Sorensen AM, Johansson P. Detection of tPAinduced hyperfibrinolysis in whole bloods by Rapid TEG, KaolinTEG, and functional fibrinogenTEG in healthy individuals. Clin Appl Thromb Hemost. 2012;18:638-644.
22. Kupesiz A, Rajpurkar M, Warrior I, Hollon W, Tosun O, Lusher J, Chitlur M. Tissue plasminogen activator induced fibrinolysisVstandardization of method using thrombelastography. Blood Coagul Fibrinolysis. 2010; 21:320-324.
23. Nielsen VG, Cohen BM, Cohen E. Elastic modular-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation. Blood Coag Fibrinolysis. 2006;17:75-81.
24. Schochl H, Frietsch T, Pavelka M, Jambor C. Hyperfibrinolysis after traumaVdifferential diagnosis of lysis patterns and prognostic value of thrombelastography. J Trauma. 2009;67:125-131.
25. Chapman MP, Moore EE, Ghasabyan A, Harr JN, Chin TL, Ramos CR, Stringham JR, Silliman CC, Banerjee A. TEG fibrinolysis above 3% is the critical value for initiation of antifibrinolytic therapy. J Trauma Acute Care Surg. In press.
26. Kotora N, Tanaka KA, Szlam F, Levy JH. The effect of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. Anesth Analg. 2005;100:1781-1785.
27. Afshari A, Wikkelso A, Brok J, Moller AM, Wetterslev J. Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev. 2011;CD007871.
28. Sankarankutty A, Nascimento B, Teodoro da Luz L, Rizoli S. TEG and ROTEM in trauma: similar test but different results? World J Emerg Surg. 2012;7(Suppl 1):S3.
29. Schöchl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, Kozek-Langenecker S, Solomon C. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)- guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care. 2010;14:R55.
30. Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, Khan S, De'ath HD, Allard S, Hart DP, et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2013;11: 307Y314.
31. Ramos CE, Moore EE, Manco-Johnson ML, Silliman CC, Chapman MC, Banerjee A. Diagnosis of hyperfibrinolysis in trauma requires further validation. J Thromb Haemost. In press.
32. Cotton BA, Harvin JA, Kostousouv V, Minei KM, Radwan ZA, Schöchl H, Wade CE, Holcomb JB, Matijevic N. Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration. J Trauma Acute Care Surg. 2012;73: 365-370.
33. Holcomb JB, Minei KM, Scerbo ML, Radwan ZA, Wade CE, Kozar RA, Gill BS, Albarado R, McNutt MK, Khan S, et al. Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. Ann Surg. 2012;256:476Y486.
34. Ives C, Inaba K, Branco BC, Okoye O, Schochl H, Talving P, Lam L, Shulman I, Nelson J, Demetriades D. Hyperfibrinolysis elicited via thromboelastography predicts mortality in trauma. J Am Coll Surg. 2012; 215:496-502.
35. McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs. 2012;72:585-617.
36. Cyklokapron (tranexamic acid) injection [package insert]. Pfizer Inc., New York, NY. 2008. Available at: www.pfizer.com/products/rx/prescription.jsp. Accessed November 10, 2012.
37. Lysteda (tranexamic acid) tablets [package insert]. Xanodyne Pharmaceuticals, Newport, Kentucky. 2009; Available at: www.lysteda.com. Accessed November 10, 2012.
38. Naoulou B, Tsai MC. Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: a systematic review. Acta Obstet Gynecol Scand. 2012;91:529-537.
39. CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376:23.
40. CRASH 2. The Use of Tranexamic Acid. Available at: http://crash2.lshtm. ac.uk/Accessed November 10, 2012.
41. Weber BJ, Kjelland CB. The use of tranexamic acid for trauma patients? CJEM. 2012;14:53-56.
42. Ker K, Kiriya J, Perel P, Edwards P, Shakur H, Roberts I. Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial. BMC Emerg Med. 2012;12:3.
43. Summary of the report of the 18th meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines, 18th Meeting, Accra, Ghana March 21-25, 2011. Available at: http://www.who.int/selection-medicines/committees/ TRS-web-summary.pdf. Accessed November 10, 2012.
44. Proposal for the Inclusion of Tranexamic Acid (Anti-FibrinolyticYLysine Analogue) in the WHO Model List of Essential Medicines. Available http://www.who.int/selection-medicines/committees/expert/17/application/ TRANEXAMIC-ACID.pdf Accessed November 10, 2012.
45. Roberts I, Shakur H, Ker K, Coats T; CRASH-2 Trial collaborators, Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2012;12:CD004896. Review.
46. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, Ker K. Anti-fibrinolytic use for minimizing perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011; Mar 16;(3):CD001886. Review.
47. Perel P, Ker K, Morales Uribe CH, Roberts I. Tranexamic acid for reducing mortality in emergency and urgent surgery. Cochrane Database Syst Rev. 2013;1:CD010245.
48. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054.
49. CRASH-2 collaborators, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011; 377:1096-1101.
50. Perel P, Salman RA, Kawahara T, Morris Z, Prieto-Merino D, Roberts I, Sandercock P, Shakur H, Wardlaw J. CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injuryVa nested randomised, placebo-controlled trial. Health Technol Assess. 2012;16: iii-xii, 1-54.
51. CRASH-2 Collaborators, Intracranial Bleeding Study. Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). BMJ. 2011;343:d3795.
52. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg. 2012;147:113-119.
53. Inaba K. Antifibrinolytics in trauma patients: does it MATTER? Comment on "Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study". Invited critique. Arch Surg. 2012;147:119.
54. Morrison JJ, Ross JD, Dubose JJ, Jansen JO, Midwinter MJ, Rasmussen TE. Association of cryoprecipitate and tranexamic acid improved survival following wartime injury: findings from theMATTERs II study. Arch Surg. 2012.
55. Available at: http://www.usaisr.amedd.army.mil/assets/cpgs/Damage- Control-Resuscitation-10-Aug-2011%20.pdf Accessed November 10, 2012.
56. Mannucci.
57. Ross J, Salman RA. The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: systematic review and meta-analysis of observational studies and randomized trials. Curr Drug Saf. 2012;7:44-54.
58. Medcalf RL. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost. 2007;5(Suppl 1):132-142.
59. Syrovets T, Simmet T. Novel aspects and new roles for the serine protease plasmin. Cell Mol Life Sci. 2004;61:873-885.
60. Jimenez JJ, Iribarren JL, Lorente L, Rodriguez JM, Hernandez D, Nassar I, Perez R, Brouard M, Milena A, Martinez R, Mora ML. Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. Crit Care. 2007;11:R117.
61. Jiménez JJ, Iribarren JL, Brouard M, Hernández D, Palmero S, Jiménez A, Lorente L, Machado P, Borreguero JM, Raya JM, et al. Safety and effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: a randomized double-blind, dose-dependent, phase IV clinical trial. J Cardiothorac Surg. 2011;6:138.
62. Godier A, Roberts I, Hunt B. Tranexamic acid: less bleeding and less thrombosis. Crit Care. 2012;16:135.
63. Guerriero C, Cairns J, Perel P, Shakur H, Roberts I; CRASH 2 trial collaborators. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PLoS One. 2011;6:e18987.
64. Levy JH. Antifibrinolytic therapy: new data and new concepts. Lancet. 2010;376:3-4.
65. Crash-3. Clinical Randomisation of an Antifibrinolytic in Significant Head Injury. London School of Hygiene and Tropical Medicine. Available at: http://crash3.lshtm.ac.uk/.
66. Dewan Y, Komolafe EO, Mejía-Mantilla JH, Perel P, Roberts I, Shakur H. CRASH-3Vtranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials. 2012;13:87.
67. Clinicaltrials.gov ID NCT01402882 Trial registration Current Controlled Trials ISRCTN15088122.
68. ClinicalTrials.gov ID NCT00872469; Protocol Number ISRCTN76912190.
69. Tranexamic acid for the treatment of postpartum haemorrhage: an international randomized, double-blind, placebo-controlled trial. London School of Hygiene and Tropical Medicine. Available at: http://www.thewomantrial.lshtm. ac.uk/. Accessed November 10, 2012.
70. The Lancet. CRASH-2 goes viral. Available at: http://www.lancet.com/ journals/lancet/article/PIIS0140673611617601/fulltext. Accessed November 10, 2012.
71. Available at: http://www.traumafoundation.org/restricted/tinymce/ jscripts/tiny-mce/plugins/filemanager/files/ask-traumacare/ ATC%20Tranexamic%20Acid%20with%20attachments.pdf. Accessed November 10, 2012.
72. Roberts I, Perel P, Prieto-Merino D, Shakur H, Coats T, Hunt BJ, Lecky F, Brohi K, Willett K; on behalf of the CRASH-2 collaborators, Effect of tranexamic acid onmortality in patientswith traumatic bleeding: prespecified analysis of data from randomised controlled trial. BMJ. 2012;345:e5839.
73. Perel P, Prieto-Merino D, Shakur H, Clayton T, Lecky F, Bouamra O, Russell R, Faulker M, Steyerberg EW, Roberts I. Predicting early death in patients with traumatic bleeding: development and validation of prognostic model. BMJ. 2012;345:e5166.
74. Pusateri AE, Weiskopf RB, Bebarta V, Butler F, Cestero RF, Chaudry IH, Deal V, Dorlac WC, Gerhardt RT, Given MB, et al. Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities. Shock. 2013;39:121-126.
75. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg. 2010;110:350-353.
76. Keyl C, Uhl R, Beyersdorf F, Stampf S, Lehane C, Wiesnack C, Trenk D. High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardiothorac Surg. 2011; 39:e114-e121.
77. Goldstone AB, Bronster DJ, Chikwe J. Predictors and outcomes of seizures after cardiac surgery: a multivariable analysis of 2, 578 patients. Ann Thorac Surg. 2011;91:514-518.
78. Manji RA, Menkis AH, Jacobsohn E. Seizures following cardiac surgery: the impact of tranexamic acid and other risk factors. Can J Anaesth. 2012; 59:6-13.
79. Kalavrouziotis D, Voisine P, Mohammadi S, Dionne S, Dagenais F. Highdose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. Ann Thorac Surg. 2012;93:148-154.
80. Hunter GR, Young GB. Seizures after cardiac surgery. J Cardiothorac Vasc Anesth. 2011;25:299-305.
81. Lecker I, Wang D-S, Romaschin AD, Peterson M, Mazer CD, Orser BA. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest. 2012;122:4654-4666.
82. Schwinn DA, Mackensen GB, Brown EN. Understanding the TXA seizure connection. J Clin Invest. 2012;122:4339-4341.
83. US Food and Drug Administration. Cyklokapron (tranexamic acid) injection. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm241709. htm. Accessed November 10, 2012.